Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

An international team of UK and US scientists discovered that the activity of macrophages -- a type of white blood cell that engulf pathogens and cancer cells -- can be used to predict whether or not ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...

Anybody who has oral, anal, or vaginal sex, or genital skin-to-skin contact with another person can get STDs — in fact, most sexually active people get one at some point in their life. STDs don’t ...